<DOC>
	<DOCNO>NCT02467504</DOCNO>
	<brief_summary>Rheumatoid arthritis ( RA ) immune-mediated inflammatory disease , characterize symmetric poly-arthritis usually involve small joint hand foot . In addition , various extra-joint manifestation may develop . Several immunomodulating agent attempt treatment RA without achieve satisfactory result . Dysfunction regulatory T ( Treg ) cell detect diverse autoimmune disease , promote interleukin-2 ( IL-2 ) . The investigator hypothesize low-dose IL-2 could novel therapy active RA patient . This clinical study test efficacy safety low dose IL-2 treatment RA . The investigator perform single-centre , double-blind pilot trial hrIL-2 RA . The investigator evaluate effectiveness safeness low-dose hrIL-2 RA randomize control study ( hrIL-2 ( N = 30 ) + Methotrexate ( MTX ) + Loxoprofen versus placebo+MTX + Loxoprofen group ( N = 30 ) ) .</brief_summary>
	<brief_title>Low-dose Recombinant Human IL-2 Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description>Each RA patient ( n=60 ) DAS &gt; 3.2 receive low-dose IL-2+MTX+ Loxoprofen placebo+MTX + Loxoprofen ( active group : placebo group =1:1 , 1 million unit every day subcutaneously ( hrIL-2 1×106 , ip , Qod ) period 14 day . After 14-day rest , another cycle start ) 3 cycle . The end point safety clinical immunologic response .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Loxoprofen</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Male female ≥18 ≤70 year age time screen Diagnosed rheumatoid arthritis Must active disease initiate DMARDs ( Disease Modifying AntiRheumatic Drugs ) Moderate severe rheumatoid arthritis screening , define disease activity score ( 28 joint ) calculate use Creactive protein formula ( DAS28CRP ) &gt; 3.2 Have give write informed consent Patient present history inflammatory joint disease Patient ongoing previous StevensJohnson syndrome , toxic epidermal necrolysis erythema multiforme Patient significantly impair bone marrow function significant anaemia , leucopenia thrombocytopenia due cause active rheumatoid arthritis Persistent infection severe infection within 3 month enrollment , Uncontrolled hypertension , uncontrolled diabetes , unstable ischemic heart disease , active inflammatory bowel disease , active peptic ulcer disease , terminal illness medical condition , opinion investigator , would put patient risk participate study , Clinically relevant cardiovascular , hepatic , neurological , endocrine , major systemic disease make implementation protocol interpretation study result difficult Severe hypoproteinemia ( e.g. , case severe liver disease nephrotic syndrome ) serum albumin &lt; 30 g/L Moderate severe impairment renal function , know serum creatinine &gt; 133μmol/L ( 1.5 mg/dl ) Patient history recent clinically significant drug alcohol abuse Impairment liver function persist ALT ( SGPT ) elevations 2fold upper limit normal Known HIV positive status Known positive serology hepatitis B C Patient hypersensitivity excipients tablet methotrexate Pregnancy Breastfeeding Women childbearing potential , except fulfill specific condition , Men wish father child course study within 24 month thereafter ( 3 month washout procedure ) Patient congenital acquire severe immunodeficiency , history cancer lymphoproliferative disease , patient receive total lymphoid irradiation Previous therapy time : DMARD include methotrexate , oral injectable gold salt , chloroquine , hydroxychloroquine , ciclosporin , azathioprine , methotrexate , sulfasalazine alkylating agent , e.g. , cyclophosphamide , chlorambucil , biological agent , e.g. , interferon , monoclonal antibody , growth factor , cytokine investigational drug antimetabolite • Therapy within previous 4 week : oral corticosteroid exceed prednisolone equivalent 10 mg/day parenteral intraarticular corticoid injection Enrollment clinical trial involve offlabel use investigational drug device , enrollment type medical research Any active infection ( include chronic localized infection ) antiinfectives indicate within 28 day prior first investigational product dose BMI ( body mass index ) 18.5 kg/m2 30 kg/m2 The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>